se of Tablet Neuroten Dm in the patients of Peripheral Diabetic Neuropathy

Phase 3

• Conditions: Health Condition 1: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhere

• Registration Number: CTRI/2024/08/071922
• Lead Sponsor: Post Graduate Institute Of Ayurved Jodhpur,Rajastan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1 Patients having cardinal symptoms of Madhumeha Upadrava like Daha, Harsha, Suptata will

be selected

2 Diagnosed cases of Diabetic Neuropathy will be included

3 Mild to moderate Neuropathy patients having Toronto score between 6 to 11 will be included

4 Both fresh and treated cases will be included in the study

5 On-going oral hypoglycaemic agents will be continued during the study

6 No other neuropathy-managing drugs are allowed during the study period

7 Patients aged between 30 to 70 years will be included of both sexes

8 Patients who are willing to sign written consent will be included

9 Patient should be capable of obeying Pathya–apathya

Exclusion Criteria

1 IDDM (Type 1 DM) will be excluded from study

2 Patient with any other serious condition or disease which impact nerves except Diabetic Peripheral Neuropathy will be excluded

3 Pregnant and lactating women will be excluded

4 Patients having any other associated clinical condition like Dementia, Parkinson, or Stroke which influence peripheral nerve function will be excluded

5 Patient having ulceration/infection of feet

6 Medical/Surgical condition limiting functional mobility

7 Non-ambulatory patients

8 who are not willing to participate / consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified